PubMed Health⌕ Search

PubMed · 17025640

Arrested segregative phase separation in capillary tubes.

Abstract

Phase separation in a capillary tube with one of the phases fully wetting the capillary wall is arrested when the typical size of the phase domains reaches the value of the diameter of the tube. The arrested state consists of an alternating sequence of concave-capped and convex-capped cylindrical domains, called "plugs," "bridges," or "lenses," of wetting and nonwetting phase, respectively. A description of this arrested plug state for an aqueous mixture of two polymer solutions is the subject of this work. A phase separating system consisting of two incompatible polymers dissolved in water was studied. The phase volume ratio was close to unity. The initial state from which plugs evolve is characterized by droplets of wetting phase in a continuous nonwetting phase. Experiments show the formation of plugs by a pathway that differs from the theoretically well-described instabilities in the thickness of a fluid thread inside a confined fluid cylinder. Plugs appear to form after the wetting layer (the confined fluid cylinder) has become unstable after merging of droplet with the wetting layer. The relative density of the phases could be set by the addition of salt, enabling density matching. As a consequence, the capillary length can in principle be made infinitely large and the Bond number (which represents the force of gravity relative to the capillary force) zero, without considerably changing the interfacial tension. Using the possibility of density matching, the relations among capillary length and capillary diameter on the one hand, and the presence of plugs and their average size on the other were studied. It was found that stable plugs are present when the capillary radius does not exceed a certain value, which is probably smaller than the capillary length. However, the average plug size is independent of capillary length. At constant capillary length, average plug size was found to scale with the capillary diameter to a power 1.3, significantly higher than the expected value of 1. Plug sizes had a polydispersity between 1.1 and 1.2 for all capillary radii for which this number could be reliably determined, suggesting a universal plug size distribution. Within plug sequences, size correlations were found between plugs with one to three plugs in between. This suggests the presence of an additional length scale.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Hans Tromp, Saskia Lindhoud. 2006-09-15. Arrested segregative phase separation in capillary tubes.. https://doi.org/10.1103/physreve.74.031604

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗